Correlation Between Oric Pharmaceuticals and Supernus Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Oric Pharmaceuticals and Supernus Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Oric Pharmaceuticals and Supernus Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Oric Pharmaceuticals and Supernus Pharmaceuticals, you can compare the effects of market volatilities on Oric Pharmaceuticals and Supernus Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Oric Pharmaceuticals with a short position of Supernus Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Oric Pharmaceuticals and Supernus Pharmaceuticals.

Diversification Opportunities for Oric Pharmaceuticals and Supernus Pharmaceuticals

-0.15

Correlation Coefficient

Oric Pharmaceuticals  Supernus Pharmaceuticals

Good diversification

The 3 months correlation between Oric and Supernus is -0.15. Overlapping area represents the amount of risk that can be diversified away by holding Oric Pharmaceuticals and Supernus Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Supernus Pharmaceuticals and Oric Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Oric Pharmaceuticals are associated (or correlated) with Supernus Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Supernus Pharmaceuticals has no effect on the direction of Oric Pharmaceuticals i.e., Oric Pharmaceuticals and Supernus Pharmaceuticals go up and down completely randomly.

Pair Corralation between Oric Pharmaceuticals and Supernus Pharmaceuticals

Given the investment horizon of 90 days Oric Pharmaceuticals is expected to under-perform the Supernus Pharmaceuticals. In addition to that, Oric Pharmaceuticals is 1.98 times more volatile than Supernus Pharmaceuticals. It trades about -0.08 of its total potential returns per unit of risk. Supernus Pharmaceuticals is currently generating about 0.16 per unit of volatility. If you would invest  3,118  in Supernus Pharmaceuticals on September 30, 2024 and sell it today you would earn a total of  600.00  from holding Supernus Pharmaceuticals or generate 19.24% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Oric Pharmaceuticals  vs.  Supernus Pharmaceuticals

Oric Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Oric Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's forward indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Supernus Pharmaceuticals

Risk-Adjusted Performance

12 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Supernus Pharmaceuticals are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of very inconsistent basic indicators, Supernus Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Oric Pharmaceuticals and Supernus Pharmaceuticals

The main advantage of trading using opposite Oric Pharmaceuticals and Supernus Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Oric Pharmaceuticals position performs unexpectedly, Supernus Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Supernus Pharmaceuticals will offset losses from the drop in Supernus Pharmaceuticals' long position.

The idea behind Oric Pharmaceuticals and Supernus Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.